Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01992562
Other study ID # PRIALT01
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date January 2014
Est. completion date December 2015

Study information

Verified date September 2018
Source OhioHealth
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 4 study being conducted at the Ohio State University Department of Neurology Multiple Sclerosis Research Program. The purpose of the study is to administer a single shot of intrathecal (injection into the space surrounding the spinal cord via a lumbar puncture or spinal tap) ziconotide as a test dose to patients who have chronic painful myelopathy (pain from spinal cord damage) or painful peripheral neuropathy (pain from nerve damage) that has not responded to other pain medicines.


Description:

Study Hypothesis: We intend to determine if a single shot trial (SST) of intrathecal (IT) ziconotide will temporarily reduce pain in these patients. In the proposed study, patients will receive two injections, one of which is the ziconotide and one which is a placebo. They will be blinded and not know which order they receive the treatment versus placebo. The results of this clinical trial will provide a focused examination of ziconotide efficacy and safety in patients with painful neuropathies or myelopathies that have not been effectively treated with other pain medications. Moreover, the use of a single shot trial (SST) IT injection in the outpatient setting will provide evidence for application of this technique in outpatient neurological clinical practice, thereby improving access to this specific patient population. Ziconotide is currently FDA approved for this indication and route of administration. Therefore, a study design that improves the feasibility of ziconotide trialing specifically in the neurology clinic (that is, single shot administration) is being used in order to ensure its broader use by neurologists who routinely care for neuropathy and myelopathy patients. Information from this study will also inform future studies of predictors for long term efficacy after pump placement.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Men or women 18 years or older.

2. Neuropathic pain due to peripheral neuropathy or myelopathy

3. Duration of condition greater than 6 months

4. Inadequate control with trials of three or more analgesic agents considered standard care for treatment of neuropathic pain; treatment failure can be either due to lack of efficacy or to intolerable side effects.

5. Documented normal CK and GFR within 6 months preceding screening.

6. Baseline BPI pain severity subscale score of >5/10

Exclusion Criteria:

1. Renal insufficiency

2. History of Myopathy or persistently elevated CK levels

3. History of prior suicide attempt or ideation

4. History of Psychosis

5. Pregnancy or breastfeeding

6. Inability or unwillingness to use contraception

7. Inability to provide consent

8. Inability to tolerate lumbar punctures

9. Receiving systemic anticoagulation therapy (eg. Coumadin)

10. Inability/unwilling to self-catheterize if indicated

11. Change (start, stop, adjust) in home medications 30 days prior to screening visit.

12. Baseline CES-D score > 30

13. Subject has previously failed ziconotide treatment

14. Other factors that in the opinion of the PI would exclude the subject from participation in the study

Study Design


Intervention

Drug:
Ziconotide

placebo


Locations

Country Name City State
United States The Ohio State University Department of Neurology Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
Aaron Boster

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Timed 25 Foot Walk Test (T25-FW) A quantitative mobility and leg function performance test based on a timed 25-foot walk. within 8 hours of injection
Primary Visual Analog Scale of Pain Intensity (VASPI) The primary outcome measure of this study is to determine the efficacy of single shot IT ziconotide in treatment of refractory neuropathic pain as a result of painful peripheral neuropathy or myelopathy and to determine the maximal decrease from baseline in VASPI (Visual Analog Scale of Pain Intensity). A responder analysis will also be performed for the VASPI. within 8 hours post injection
Secondary Numerical Rating Scale of Pain (NRS) Used to measure pain intensity on a 0-10 scale. within 8 hours of Injection
Secondary Brief Pain Inventory (BPI) Scale Used to assess the severity of pain and the impact of pain on daily functions. within a week of Injection
Secondary Pittsburgh Sleep Quality Index (PSQI) Used to measure the quality and patterns of sleep in adults. within a week of injection
Secondary Patient Global Impression of Change (PGIC) Used to assess the patient's belief about the efficacy of their treatment. within 8 hours of injection
See also
  Status Clinical Trial Phase
Completed NCT02125006 - The Effect of an Inter-Disciplinary Program, Including MBSR, in Breast Cancer Survivors With Chronic Neuropathic Pain N/A
Terminated NCT01667029 - Study of Sulfasalazine in Treating Painful Neuropathy Phase 2
Completed NCT01363284 - Pretreatment Identification of Duloxetine Success in Neuropathic Pain Patients N/A
Completed NCT02758197 - Online MBSR Program for Cancer Survivors With Chronic Neuropathic Pain N/A